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طيف اضطرابات االختزان يف اجُلَسْيَماِت احلَالَّة عند 
األطفال يف ُعمان
املنذر املعويل، �سوريندرا جو�سي، رو�سان كول، علي عبداهلل املعويل، هالل �سالح ال�سديري، بدر حممد العمري، 
اآمنة حممد الفطي�سي
امللخ�ص: الهدف: درا�سة طيف ا�سطرابات الختزان يف اجُل�َسْيَماِت احَلالَّة عند الأطفال يف ُعمان. طيف ا�سطرابات الختزان يف اجُل�َسْيَماِت 
احَلالَّة هي جمموعة غري متجان�سة من الأمرا�ض الأي�سية املوروثة. هناك درا�سات قليلة حول انت�سار هذه املجموعة عند الولدة وبعدها 
86 طفال م�سابا با�سطرابات الختزان يف اجُل�َسْيَماِت احَلالَّة مت ت�سخي�سهم خالل ت�سع  الطريقة: قمنا بدرا�سة  يف �سبه اجلزيرة العربية. 
�سنوات، من يونيو 1998 اإىل مايو 2007. وقد مت جمع البيانات ال�رسيرية املف�سلة، مبا يف ذلك ال�سن عند بداية املر�ض واجلن�ض وطريقة 
يف  احلالة  اجل�سيمات  يف  الختزان  ا�سطرابات  طيف  انت�سار  اأن  اإىل  املتوفرة  البيانات  ت�سري  النتائج:  القرابة.  �سلة  ووجود  املر�ض  بدء 
�سلطنة ُعمان 1 لكل 4700 ولدة حية. وكانت ال�سحامات ال�سفينغولية املجموعة الأكرث �سيوعا بن�سبة )47.7%(، تليها الليبوفو�سينية 
ال�سريويدية الع�سبية )23.2%( من ثم عديد ال�سكاريد املخاطي )23.2%(. كانت ن�سبة زواج الأقارب عالية اإذ بلغت 87.5%. اخلال�صة: 
متثل املعطيات  مدى انت�سار ا�سطرابات طيف ا�سطرابات الختزان يف اجل�سيمات احلالة يف �سلطنة ُعمان، والتي ُتعد من اأحد اأكرث جمتمعات 
ال�رسق الأو�سط يف انت�سار زيجات الأقارب. 
مفتاح الكلمات: ا�سطرابات تخزين اجُل�َسْيَماِت احَلالَّة، ُعمان؛ انت�سار؛ العرب. 
abstract: Objectives: The aim of this study was to look at the spectrum of paediatric lysosomal disorders in 
Oman. Lysosomal storage disorders (LSDs) are a heterogeneous group of inherited metabolic diseases. Few studies 
on the birth prevalence and prevalence of LSDs have been reported from the Arabian Peninsula. Methods: We 
studied 86 children with LSDs diagnosed over a period of nine years, from June 1998 to May 2007. Detailed clinical 
data, including age of onset, sex, age and mode of first presentation, and presence of consanguinity were collected. 
Results: Our data showed the combined birth prevalence for all LSDs in Oman to be around 1 in 4,700 live births. 
Sphingolipidoses was the most common group of disorder encountered (47.7%), followed by neuronal ceroid 
lipofuscinoses (NCL) (23.2%) and mucopolysaccharidoses (MPS) (23.2%). The proportion of consanguineous 
marriages in our series was found to be 87.5%. Conclusion: Our data represent the birth prevalence and clinical 
spectrum of such disorders in Oman, one of the highly consanguineous societies in the Middle East. 
Keywords: Lysosomal storage disorders; Oman; Prevalence; Arabs.
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Advances in Knowledge
- This is the first report of lysosomal storage disorders (LSDs) from Oman. The study highlights the birth prevalence, spectrum, and clinical 
characteristics of various disorders, and their relevance in a population with a very high consanguinity rate.
- The study’s findings add to the knowledge of hereditary disorder screening in the people of the Arabian Peninsula.
application to patient care
- Knowledge of LSDs will direct appropriate and necessary testing programmes for patients in Oman.
- The importance of high-risk testing lies in the prevention of LSDs by premarital and prenatal screening, as well as in early initiation of 
treatment, when available.
Lysosomal storage disorders (LSDs) are relatively rare inborn errors of metabolism, with a combined global birth prevalence of 1 in 1,500 to 7,000 live births.1 They represent a group of more than 40 distinct genetic disorders.2,3 Deficiency of lysosomal proteins or, 
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less frequently, non-lysosomal proteins involved 
in lysosomal biogenesis, result in the accumulation 
of non-metabolised macromolecules.4 Most of 
these disorders are inherited in an autosomal 
recessive manner, except Fabry’s disease and 
mucopolysaccharidoses type II (MPS II) which are 
inherited in an X-linked recessive manner.4
Major groups of LSD disorders include MPS, 
lipidoses, glycogenoses, and oligosaccharidoses.4 
Most disorders present clinically with multi-system 
involvement. Common clinical features involve 
bony dysplasia, hepatosplenomegaly, central 
nervous system dysfunction, haematological 
abnormalities, and coarse hair and facial features. 
There are many phenotypical similarities within 
the categories. Potential treatments for some of 
these disorders are available in the form of enzyme 
replacement therapy (ERT) and bone marrow 
transplantation (BMT).
Most of the reports on LSD’s birth prevalence 
and general prevalence are from Western 
countries.4–9 Data on the frequency of LSDs in 
the Arab population are quite sparse; however, a 
recent report described prevalence of inborn error 
of metabolism (IEM) in Oman.10 The aim of  this 
study was to investigate the relative frequency of 
various LSDs in Oman. Estimating the baseline 
birth prevalence is of increasing importance given 
the interest in newborn screening for LSDs, and 
the availability of expensive ERT and substrate 
reduction therapy.
Methods
Sultan Qaboos University Hospital (SQUH) in 
Muscat, Oman, is the main referral centre for 
metabolic genetic diseases in the country. We 
studied 86 paediatric cases referred over a period 
of nine years from June 1998 to May 2007. The 
institution’s ethical committee approved the study. 
Detailed clinical data, including sex, age of onset 
of disease, age at diagnosis, mode of presentation, 
family history, consanguinity rates, and high-risk 
screening results were collected. Detailed results of 
laboratory investigations and medical imaging were 
obtained. The Willink Biochemical Genetics Unit in 
Manchester, UK, (which has UK Clinical Pathology 
Accreditation [CPA]) assessed the lysosomal 
enzyme levels from blood samples of all patients. 
All patients in this study had a confirmatory 
enzymatic diagnosis. Genetic mutation analysis 
was only performed in cases of patients who 
received enzyme replacement therapy (ERT) or a 
bone marrow transplant (BMT). We determined 
the annual number of live births in Oman from the 
National Health Statistics for the years in which our 
study subjects were born. The total number of live 
births and the total number of LSD patients then 
were averaged to a total number of cases per year. 
The birth prevalence rate of LSDs was calculated by 
dividing the average number of postnatal diagnoses 
per year by the average number of live births per 
year between 1998 and 2007. 
Results
Between June 1998 and May 2007, a total of 
86 patients (male to female ratio = 1:0.7) were 
diagnosed with LSD. The average number of 
live births during the study period was 45,000 
per year. The combined birth prevalence for all 
LSDs was therefore 1 in 4,700 live births per 
year. Sphingolipidoses as a group was the most 
frequent LSD (47.7%), followed by neuronal ceroid 
lipofucinoses (NCL) (23.2%) and MPS (23.2%). 
Detailed frequencies of LSDs are presented in Table 
1. The proportion of consanguineous marriages in 
the referred families was 87.5%, and 35% of patients 
had a sibling with a similar illness at the time of 
diagnosis. The patients ranged in age from 3 days 
old (neonates) to 18 years of age. A total of 47.5% 
patients became symptomatic between 1 and 6 
months of age, 27.5% between 6 months and 1 year 
old, and 25% presented with symptoms after one 
year old. Among sphingolipidosis, Sandhoff disease 
was one of the most commonly encountered 
diseases (15.1%), followed by Gaucher disease 
(8.1%). Late infantile neuronal ceroid lipofuscinosis 
(NCL) was the single most common disease 
diagnosed in our series (23%). The majority of these 
patients presented between 1 to 4 years of age with 
regression in their development and intractable 
seizures. It was noted that all the children with 
disease had myoclonic seizures, microcephaly and 
maculopathy. In general, global developmental 
delay/regression (40%), coarse facial features and 
hepato-splenomegaly (30%) were the most common 
presenting features at diagnosis. Other presenting 
features were nystagmus, abdominal distension, 
deafness, recurrent infections, and failure to thrive. 
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A couple of patients were diagnosed by testing done 
to siblings previously diagnosed with the same 
disease.
Discussion
The LSDs are rare disorders resulting from the 
accumulation of substrates within the lysosomes. 
These disorders are under-diagnosed and their 
birth prevalence is underestimated.1 The exact birth 
prevalence of LSDs in the Arab population remains 
unknown. This is the first report of LSDs in Oman 
which highlights the birth prevalence, spectrum, 
and clinical characteristics of the various disorders 
identified during a nine-year period. It is also one 
of the few studies to report the birth prevalence 
and prevalence of LSDs in one of the highly 
consanguineous societies of the Middle East. In our 
study, we estimated the combined birth prevalence 
rate of LSDs at 1 per 4,700 live births. In Australia, 
the birth prevalence rate was estimated to be 1 per 
9,000, excluding prenatal diagnosis.4 Poorthuis et al. 
reported the combined birth prevalence for all LSDs 
in the Netherlands as 14 per 100,000 live births.5 
In Oman, the birth prevalence rate of all inborn 
errors of metabolism as a group was reported as 1 
per 1,555 out of which 25% were LSDs.10 This is a 
much higher birth prevalence than that reported 
in Caucasians. In Saudi Arabia, 125 cases of LSDs 
of different types were reported in births occurring 
over a three-year period.9 
Sphingolipidoses was the most frequent LSD 
encountered in our study. These cases constituted 
47.7% of cases. This finding was consistent with 
and comparable to different reports. Many of these 
disorders present in infantile form. In our group, 
45.7% of the patients developed symptoms between 
the ages of 1 and 6 months. Sandhoff disease was 
one of the most commonly encountered diseases 
(15.1%). It is a relatively rare metabolic disease, 
but seen more commonly in certain populations, 
including the Argentinean Creoles, the Metis 
Indians, and the Lebanese.11 The birth prevalence 
rate of Sandhoff disease is 1 per 309,000 births in 
non-Jewish populations.12 Fourteen of the 125 LSD 
patients in Saudi Arabia (11.2%) presented with 
Sandhoff disease.9
Gaucher disease was confirmed in 8.1 % (7/86) 
in the study group. Worldwide, Gaucher disease 
has a birth prevalence of approximately 1.5 per 
100,000 births; however, Ashkenazi Jews have a 
higher frequency of this disorder. In Saudi Arabia, 
Ozand et al. reported that 3 patients out of the 125 
total patients seen with LSD had Gaucher disease. 
A retrospective study for LSDs from the United 
Arab Emirates (UAE) reported only four cases of 
Gaucher disease.13 At SQUH, two siblings with type 
III Gaucher disease with a homozygous L444P/
L444P mutation have been undergoing ERT for 
Table 1: Number of patients and relative frequency 
of different categories of lysosomal storage disorders 
(LSDs)
Diagnosis SUB-Types No. %
Sphingolipidoses 41 47.7
Gaucher disease
Type 1 2 2.3
Type 2 1 1.2
Type 3 4 4.7
Niemann-Pick 
disease A and B 3 3.5
Metachromatic 
leukodystrophy 8 9.3
Krabbe disease 1 1.2
GM1 Gangliosidosis 4 4.7
Tay-Sachs disease 5 5.9
Sandhoff disease 13 15.1
Mucopolysaccharidoses 20 23.2
Type I 3 3.5
Type II 2 2.3
Type III 7 8.1
Type IV 4 4.7
Type VI 3 3.5
Type VII 1 1.2
Mucolipidosis 1 1.2
I cell disease 1
Oligosaccharidoses 2 2.3
Siladosis 2
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eight and seven years, respectively. Although one 
of the children suffered from a severe progressive 
course of the disorder, he has shown remarkable 
improvement in terms of organomegaly and 
haematological parameters as a result of the 
treatment. His younger sibling was diagnosed and 
began ERT much earlier, at four months of age, and 
to date his mental development is improving. We 
observed that early treatment offers much better 
outcomes, except in the case of ophthalmoplegia, 
the course of which could not be altered. 
Late infantile NCL was the single most common 
disease diagnosed in our cohort. A series of eleven 
cases had previously been reported, with most of 
the patients being from five families.14  Late-infantile 
NCL, or Jansky-Bielschowsky disease (CLN2 type), 
was the most common type of NCL seen.14 Over 
time, the number of cases had increased from nine 
to twenty families. In general, CLN2 remains the 
most frequently encountered type of NCL in Oman. 
However, other types of NCL are now diagnosed 
in Omani patients due to better availability of 
diagnostic tests. NCL is not an uncommon disease 
in Arab populations. Recently, Goldberg-Stern 
et al. reported two siblings of Israeli-Arab origin 
with CLN2 having a novel mutation.15 Taschner et 
al. reported a patient with CLN3 from Morocco.16 
Sarpong et al. reported a large consanguineous 
Lebanese family with five affected siblings with 
a protracted course.17 They had juvenile CLN 
associated with a novel CLN3 mutation (p.Y199*). 
Al-Muhaizea et al. reported on three families from 
Saudi Arabia with a variant of late infantile NCL, 
one of them having a novel mutation in the CLN6 
gene.18 Zelnik et al. described a different variant of 
CLN (CLN8) in a 10-year-old Israeli-Arab boy.19
MPS as a group constituted 23.2% of the total 
LSD cases. Most of the subtypes in our group were 
evenly distributed. However, MPS III was the most 
frequently noted subtype. Ozand et al. reported 19 
patients with MPS IV out of 30 total patients with 
MPS. In Tunisia, the birth prevalence of MPS IVA 
was higher than in other communities (2.8:100,000). 
We treated one child with severe MPS I by ERT for 
9 months in preparation for a BMT. This child no 
longer needs ERT after a successful bone marrow 
engraftment. 
The  proportion of consanguineous marriages in 
the Omani population in general is 56%.20,21 About 
24.1% of marriages were reported between first 
cousins, 11.8% between second cousins, and 20.4% 
of marriages were within specific tribal groups.20 
The proportion of consanguineous marriages in 
our patients’ families was 87.5%, with most of those 
being first- and second-cousin marriages. 
Interestingly, 35% (30/86) of patients had a sibling 
with a similar illness at diagnosis. Only two patients 
in our series were diagnosed through high-risk 
screening. The importance of high-risk testing 
lies in prevention by premarital and prenatal 
screening, as well as in early initiation of treatment 
when available. It also helps in identifying those 
families who may benefit from appropriate genetic 
counselling, and it is strongly recommended to 
initiate such testing programmes for high-risk 
families.22,23 High-risk testing programmes have 
now been established in Oman. 
Conclusion
In this study, we report a combined birth prevalence 
of 1 in 4,700 live births for LSD in Oman. The 
limitation in our study is that it is retrospective and 
hospital-based. Additionally, we may have missed 
some cases which were not referred to SQUH. 
Therefore, this study likely underestimates the birth 
prevalence; diagnosis through a paediatric hospital 
setting such as ours will exclude the milder forms of 
the disease that may present in adulthood. There is 
also a bias due to missed diagnosis or death before 
diagnosis. Such factors cause an underestimation 
of the real prevalence. Oman’s birth prevalence is 
less than that reported in other Gulf countries, such 
as Saudi Arabia. A testing programme for high-risk 
families in Oman has been successfully established 
at SQUH. A prospective study, along with a national 
screening programmes would help identify the 
exact birth prevalence of LSDs in Oman. 
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